We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
5.00 | 0.29% | 1,733.50 | 1,732.50 | 1,733.00 | 1,739.50 | 1,724.50 | 1,733.00 | 4,237,056 | 16:35:18 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 14.48 | 71.35B |
Date | Subject | Author | Discuss |
---|---|---|---|
24/7/2017 12:13 | Probably explains this: Pharmaceutical giant, Glaxo Smith Kline, has pulled out of building a new £350m biopharm drugs facility in Ulverston. The decision throws doubt onto the future of the town's existing site, which could be sold by GSK. | tradermichael | |
24/7/2017 12:09 | Just a note that GSK has manufacturing unit in India for cheap labour . | action | |
24/7/2017 12:07 | J&J are due to present data today on their hiv vaccination phase 11 trial. | essentialinvestor | |
24/7/2017 11:53 | Had a small amount @ '88. | essentialinvestor | |
24/7/2017 10:12 | Bear trap before Wednesday | ny boy | |
24/7/2017 09:56 | Oh dear. :-( | philanderer | |
24/7/2017 08:31 | And why sell it anyway? If you're going to have a Consumer Products 'division', then strengthen it, taking full advantage of distributors, marketing network etc.. Surely this enables profits to generate support for pharma research/acquisition | tradermichael | |
24/7/2017 08:08 | How does disposing of the UK rights to Horlicks and a small nutrition brand mark a shift away from consumer products. | essentialinvestor | |
23/7/2017 23:23 | GSK's Walmsley to boost its pharma division Emma Walmsley, who succeeded Andrew Witty as GSK's chief executive in April, made her first move to shift the company's focus away from consumer healthcare to double down on its pharmaceuticals division last week with the sale of the Horlicks drinks brand. Walmsley also announced millions of pounds of additional investment to support the manufacture of respiratory and HIV medicines in the UK. The company's pharma division accounts for more than half of its £27.9bn in annual sales. An analyst at Morgan Stanley signalled to the Sunday Telegraph that GSK's pharma division is still lagging behind its rivals. Vincent Meunier said he would welcome “a more modern drugs business, more comparable to its peers” at GSK. Walmsley is expected to elaborate on her plans for overhauling drug research at the company’s first-half results on Wednesday. | ny boy | |
23/7/2017 11:47 | Yep, its all about the dividend .... "Dividend In the Q1 2017 press release we made the following comment on returns to shareholders: “GSK expects to pay an annual ordinary dividend of 80p for 2017. Future returns to shareholders of surplus capital will be subject to the Group’s strategic progress, visibility on the put options associated with ViiV Healthcare and the Consumer Healthcare joint venture and other capital requirements.” | tradermichael | |
23/7/2017 07:18 | Interims Wednesday | ny boy | |
21/7/2017 16:07 | GSK is now also proposing the drug for those patients already adequately controlled on an ICS/LABA combination. As part of its submission to the European Medicines Agency, GSK has shown positive data from a lung function study that concluded that patients who have well-controlled asthma are able to switch from twice-daily fluticasone propionate/salmetero | fangorn2 | |
21/7/2017 13:11 | Q2 earnings next week - Wednesday I believe. | fangorn2 | |
20/7/2017 17:19 | The CER numbers will shine more light on the subject. | alphorn | |
20/7/2017 17:07 | While of course there is a relationship between revenues and USD:GBP, this focus on the exchange rate is also somewhat over the top given that GBP is still nowhere compared to fx pre-Brexit and a few tiny moves back isn't going to change this. Emma W making all the right moves so far, this will be 1700+ as soon as volume returns to the market and the US shuts up about healthcare. | romeike | |
20/7/2017 15:49 | GBP getting hit today. | alphorn | |
20/7/2017 15:18 | NY Boy - it's gonna have to be a long wee! | solomon | |
20/7/2017 15:05 | Excellent, GS have an agenda, should go to 1715p min, if 1636.5 can be taken out this wee, | ny boy | |
20/7/2017 12:08 | 20th july Goldmans buy tp 1900p reiterates | philanderer | |
20/7/2017 11:28 | Needs to take out 1636.5p to make a move to 1652 & 1672p | ny boy | |
20/7/2017 10:55 | Surely oversold at current levels, I think we'll see another go at breaking 1715p before summers over. Ex div in exactly 3 weeks for another nice quarterly divi | ny boy | |
19/7/2017 19:16 | So the first of major restructuring announcements to come under the new CEO imv. | essentialinvestor | |
19/7/2017 17:21 | Added further to my long position this morning. | alphorn | |
19/7/2017 17:00 | Glaxo to axe 320 UK jobs in manufacturing shake-up The FTSE 100 giant has announced a reorganisation of factories in Britain three months after its new chief executive took charge. | philanderer |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions